COMP <GO>
BRKR vs BIO // OPERATING MARGIN
Bruker Corporation (NASDAQ) VS. Bio-Rad Laboratories Inc. (NYSE) • 15-METRIC TALLY: BRKR 4
— BIO 10
▲ OPERATING MARGIN LEADER: BRKR
LAST: $55.69 (-2.42%) • MKT CAP: $8.70B
operating-margins
2.00%
LAST: $366.16 (-1.62%) • MKT CAP: $9.95B
operating-margins
1.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BRKR VS. BIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BRKR | BIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.90% | 51.90% | -6.00 | BIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.30% | 0.50% | +0.80 | BRKR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 75.7x | 60.4x | +15.30 | BIO | /valuation <GO> |
| Free Cash Flow Yield | 0.46% | 3.64% | -3.18 | BIO | /fcf-yield <GO> |
| Operating Margin ACTIVE | 2.00% | 1.80% | +0.20 | BRKR | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 29.40% | -29.60 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | 2.10% | 0.70% | +1.40 | BRKR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.24% | 0.00% | +0.24 | BRKR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.81 | 3.59 | -0.78 | BIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | BIO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.8 | 50.1 | -4.30 | BIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.04 | -0.07 | BIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 12.6x | +9.40 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.70B | $9.95B | -$1.26B | BIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BRKR REV | BIO REV | BRKR GROSS % | BIO GROSS % | BRKR FCF | BIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.44B | $2.58B | 45.9% | 51.9% | $43.3M | $374.6M |
| FY 2024 | $3.37B | $2.57B | 49.0% | 53.7% | $136.0M | $289.6M |
| FY 2023 | $2.96B | $2.67B | — | — | $216.7M | $254.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BRKR // BETA 0.97
BIO // BETA 1.04